Key Metrics 
Check Before You Invest 
10 Yrs X-Ray 
Valuation 
Analyst Note 
Qtr. Results 
Financials 
News 
About
Anthem Biosciences Ltd (ANTHEM)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 544449 NSE: ANTHEM Pharmaceuticals & Drugs | Mid Cap | Anthem Biosciences Share Price
₹940.25 -1.45 (-0.15%)
As on 11-Sep'26 14:43
Anthem Biosciences Ltd (ANTHEM)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 544449 NSE: ANTHEM Pharmaceuticals & Drugs | Mid Cap | Anthem Biosciences Share Price
₹940.25 -1.45 (-0.15%)
As on 11-Sep'26 14:43
Key Metrics
Valuation Multiples
Market Cap
₹53,067 Cr.
Current Price
₹940.3
52-Week Low / High
₹579 / 977
TTM EPS
₹10.2
TTM Sales
₹2,002 Cr.
Book Value per Share
₹55.5
P/E Ratio
92.14
Higher than its 5-year historical median
Industry PE
54.3
Price to Book (P/B)
16.96
Higher than its 5-year historical median
Price to Sales (P/S)
26.50
Higher than its 5-year historical median
EV/EBITDA
55.58
Higher than its 5-year historical median
Dividend Yield
0.21%
Profitability Efficiency
Return on Equity (ROE)
21.98%
Outperforms industry median
Return on Capital Employed (ROCE)
29.62%
Outperforms industry median
Return on Assets (ROA)
18.06%
Operating Profit Margin
39.3%
Net Profit Margin
27.86%
Gross Profit Margin
45%
Growth Momentum
1-yr vs 3-yr growth
1-yr vs 3-yr growth
Sales Growth (1 Year)
Slowing versus 3-year growth rate
13.51%
Operating Profit Growth (1 Year)
Slowing versus 3-year growth rate
24.28%
Net Profit Growth (1 Year)
Improving versus 3-year growth rate
31.14%
Asset Quality
Promoter Holding
71.42%
Pledged shares (%) of Promoter's holding (%)
0.00%
Reserves
₹3,017 Cr.
Equity
₹112.7 Cr.
Face Value
₹2
All Time Low / High
₹579.45 / 977.00
Check Before You Invest
Quality
Very GoodValuation
Somewhat OvervaluedCheck Valuation charts
Price Trend
Strong
Is Anthem Biosciences Ltd a good quality company?
Anthem Biosciences Ltd is a good quality company, based on a consistently good multi-year financial track record.
This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.
We have analysed the performance of the company on the following:
-
How has it performed on generating Profits?
By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.
-
How efficiently has it utilized Capital?
By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.
-
How is it managing its Debt?
By checking its Debt to Equity and Cash Flow from Operations.
How does Anthem Biosciences Ltd performance compare with that of its Peers?
Revenue growth of Anthem Biosciences Ltd vs industry peers?
Anthem Biosciences Ltd revenue CAGR is 13.62%, compared to the industry median CAGR of 9.58%, indicating faster growth and gaining its market share.
Promoter shareholding and pledge status of Anthem Biosciences Ltd?
Promoters hold 71.42% of the Anthem Biosciences Ltd, with 0.00% of their stake pledged, indicating no pledge risk.
Stock return of Anthem Biosciences Ltd over the last decade?
Over the last 1 year(s), the stock has delivered a CAGR of 16.47% based on the current price.
10 Year X-Ray :
Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year endData adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
What is a Financial Track Record? How to read this chart in order to understand the data present here?
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Anthem Biosciences Ltd has performed well in majority of the past ten years indicating its past ten year financial track record is very good
Value Creation ⓘ
| Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % ⓘ | 29.4% | 17.2% | 25.9% | 25.6% | 55.4% | 51% | 31.2% | 25% | 30.8% | 31.3% | - |
| Value Creation Index ⓘ | 1.6 | 0.5 | 1.3 | 1.3 | 3.9 | 3.5 | 1.8 | 1.2 | 1.2 | 1.8 | - |
Growth Parameters ⓘ |
|||||||||||
| Sales ⓘ | 357 | 462 | 626 | 633 | 1,103 | 1,231 | 1,057 | 1,418 | 1,841 | 2,089 | 1,935 |
| Sales YoY Gr. | - | 29.6% | 35.5% | 1.1% | 74.4% | 11.6% | -14.2% | 34.1% | 29.9% | 13.5% | - |
| Adj EPS ⓘ | 1.2 | 0.6 | 1.4 | 1.6 | 4.8 | 7 | 6 | 6.5 | 9 | 11.5 | 11.1 |
| YoY Gr. | - | -51.3% | 141.1% | 20.7% | 195.1% | 44.7% | -14.5% | 9.9% | 37.2% | 28.3% | - |
| BVPS (₹) ⓘ | 4 | 4.6 | 6.1 | 7.8 | 12.7 | 23.8 | 30.5 | 34.6 | 43.6 | 56.1 | 57.7 |
| Adj Net Profit ⓘ | 62.7 | 30.5 | 73.4 | 88.5 | 265 | 397 | 339 | 366 | 501 | 647 | 624 |
| Cash Flow from Ops. ⓘ | 0 | 0 | 196 | 166 | 278 | 333 | 319 | 164 | 300 | 889 | - |
| Debt/CF from Ops. ⓘ | 0 | 0 | 1 | 1 | 0.4 | 0.1 | 0.4 | 1 | 0.4 | 0.1 | - |
CAGR ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | 21.7% | 13.6% | 25.5% | 13.5% | ||||
| Adj EPS ⓘ | 29.2% | 19.1% | 24.6% | 28.3% | ||||
| BVPSⓘ | 34.2% | 34.6% | 22.5% | 28.6% | ||||
| Share Price | - | - | - | 14.6% | ||||
Key Financial Parameters ⓘ
| Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | 36.8 | 12.8 | 25 | 23.5 | 47.2 | 38.6 | 21.9 | 19.9 | 22.8 | 22.9 | 19.5 |
| Op. Profit Mgn % ⓘ | 30.5 | 26.2 | 27.4 | 28.8 | 37.6 | 46.2 | 40.8 | 35.7 | 37.5 | 40.8 | 40.7 |
| Net Profit Mgn % ⓘ | 17.6 | 6.6 | 11.7 | 14 | 24 | 32.3 | 32.1 | 25.8 | 27.2 | 31 | 32.3 |
| Debt to Equity ⓘ | 0.9 | 1 | 0.6 | 0.4 | 0.1 | 0 | 0.1 | 0.1 | 0 | 0 | - |
| Working Cap Days ⓘ | 148 | 171 | 164 | 172 | 126 | 161 | 220 | 227 | 268 | 251 | 150 |
| Cash Conv. Cycle ⓘ | 73 | 89 | 79 | 87 | 50 | 63 | 98 | 110 | 115 | 100 | 122 |
Valuation of Anthem Biosciences - Consolidated
Analyst's Notes
No data found!
Management X-Ray
Shareholding Pattern
Promoter's Holding & Share Pledging
| Pledged * | 0.00 | 0.00 | 0.00 | 0.00 |
* Pledged shares as % of Promoter's holding (%)
Financials
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 248 | 308 | 356 | 633 | 1,103 | 1,231 | 1,057 | 1,419 | 1,845 | 2,124 |
| Operating Expenses ⓘ + | 178 | 215 | 248 | 451 | 696 | 664 | 634 | 914 | 1,174 | 1,290 |
| Operating Profit ⓘ | 70 | 94 | 108 | 182 | 408 | 567 | 423 | 505 | 671 | 834 |
| Operating Profit Margin (%) | 28.3% | 30.4% | 30.4% | 28.8% | 37.0% | 46.1% | 40.0% | 35.6% | 36.4% | 39.3% |
| Other Income ⓘ + | 3 | 5 | 7 | 21 | 37 | 49 | 85 | 64 | 86 | 156 |
| Interest ⓘ | 6 | 5 | 5 | 20 | 17 | 12 | 9 | 10 | 11 | 7 |
| Depreciation ⓘ | 10 | 21 | 22 | 62 | 62 | 58 | 64 | 82 | 89 | 134 |
| Profit Before Tax ⓘ | 58 | 73 | 88 | 121 | 366 | 546 | 497 | 477 | 657 | 824 |
| Tax ⓘ | 19 | 23 | 22 | 28 | 94 | 141 | 112 | 110 | 206 | 232 |
| Profit After Tax | 39 | 50 | 66 | 93 | 271 | 406 | 385 | 367 | 451 | 592 |
| PAT Margin (%) | 15.7% | 16.3% | 18.6% | 14.7% | 24.6% | 32.9% | 36.4% | 25.9% | 24.5% | 27.9% |
| Adjusted EPS (₹) | 0.7 | 0.9 | 1.2 | 1.7 | 4.9 | 7.1 | 6.8 | 6.6 | 8.1 | 10.5 |
| Dividend Payout Ratio (%) | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 19% |
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | |||||||||||
| Shareholders Fund + | 102 | 151 | 223 | 422 | 701 | 1,355 | 1,741 | 1,925 | 2,376 | 3,009 | |
| Debt + | 77 | 119 | 191 | 121 | 100 | 35 | 125 | 233 | 90 | 32 | |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Trade Payables | 24 | 26 | 33 | 58 | 77 | 65 | 72 | 101 | 110 | 75 | |
| Others Liabilities ⓘ | 31 | 59 | 62 | 175 | 213 | 271 | 167 | 219 | 373 | 489 | |
| Total Liabilities ⓘ | 235 | 355 | 510 | 776 | 1,091 | 1,726 | 2,105 | 2,477 | 2,949 | 3,606 | |
Fixed Assets | |||||||||||
| Net Fixed Assets ⓘ + | 91 | 86 | 258 | 306 | 361 | 329 | 449 | 483 | 705 | 783 | |
| CWIP ⓘ | 22 | 75 | 44 | 50 | 19 | 154 | 164 | 345 | 297 | 264 | |
| Investments ⓘ | 2 | 8 | 27 | 99 | 209 | 273 | 499 | 472 | 433 | 1,007 | |
| Inventories | 37 | 47 | 58 | 125 | 35 | 58 | 129 | 211 | 340 | 125 | |
| Trade Receivables | 57 | 84 | 74 | 105 | 255 | 326 | 274 | 490 | 450 | 591 | |
| Cash Equivalents | 2 | 4 | 11 | 22 | 41 | 349 | 343 | 184 | 172 | 275 | |
| Others Assets ⓘ | 24 | 51 | 38 | 69 | 171 | 237 | 246 | 292 | 550 | 561 | |
| Total Assets ⓘ | 235 | 355 | 510 | 776 | 1,091 | 1,726 | 2,105 | 2,477 | 2,949 | 3,606 | |
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash Flow From Operating Activity ⓘ + | 0 | 0 | 0 | 166 | 278 | 333 | 306 | 140 | 271 | 844 |
| Cash Flow From Investing Activity ⓘ + | 0 | 0 | 0 | -109 | -196 | -205 | -376 | -221 | -147 | -702 |
| Cash Flow From Financing Activity ⓘ + | 0 | 0 | 0 | -48 | -63 | 181 | 64 | -77 | -136 | -40 |
| Net Cash Flow ⓘ | 0 | 0 | 0 | 9 | 18 | 308 | -6 | -158 | -12 | 103 |
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | 49.99 | 41.23 | 36.02 | 28.84 | 48.3 | 39.44 | 24.89 | 20.04 | 20.99 | 21.98 |
| ROCE (%) | 39.87 | 34.59 | 27.35 | 28.38 | 55.36 | 50.94 | 31.08 | 24.21 | 28.55 | 29.62 |
| Asset Turnover Ratio | 1.19 | 1.04 | 0.82 | 0.98 | 1.18 | 0.87 | 0.55 | 0.62 | 0.68 | 0.67 |
| PAT to CFO Conversion(x) | 0 | 0 | 0 | 1.78 | 1.03 | 0.82 | 0.79 | 0.38 | 0.6 | 1.43 |
| Working Capital Days | ||||||||||
| Receivable Days | 64.50 | 83.40 | 80.80 | 51.60 | 59.50 | 86.10 | 103.70 | 98.30 | 92.80 | 87 |
| Inventory Days | 50.40 | 49.60 | 53.60 | 52.90 | 26.60 | 13.80 | 32.40 | 43.80 | 54.40 | 38.90 |
| Payable Days | 85.50 | 69.80 | 79.60 | 66.60 | 54.40 | 63.30 | 73.60 | 52.60 | 51.70 | 41.60 |
Top 5 Mutual Funds Holding
Last Visited Stocks
Announcements
Anthem Biosciences Ltd FAQs
The current trading price of Anthem Biosciences on 11-Sep-2026 14:43 is ₹940.2.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 10-Sep-2026 the market cap of Anthem Biosciences stood at ₹53,067.4 Cr
The latest P/E ratio of Anthem Biosciences as of 10-Sep-2026 is 85.01.
The latest P/B ratio of Anthem Biosciences as of 10-Sep-2026 is 16.31.
The 52-week high of Anthem Biosciences is ₹977.0 and the 52-week low is ₹579.5.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Anthem Biosciences is ₹1,935 ( Cr.) .
Past 10 year's financial track record analysis by Moneyworks4me indicates that Anthem Biosciences Ltd is a good quality company.
The key valuation ratios of Anthem Biosciences Ltd's currently when compared to its past seem to suggest it is in the Somewhat overvalued zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Strong which suggest that the price of Anthem Biosciences Ltd is likely to Rise in the short term. However, please check the rating on Quality and Valuation before investing
About Anthem Biosciences Ltd
Anthem Biosciences Limited was originally incorporated as ‘Anthem Biosciences Private Limited’ under the provisions of the Companies Act, 1956, pursuant to a certificate of incorporation dated June 13, 2006, issued by RoC. Subsequently, the company was converted from a private company to a public company, pursuant to a board resolution dated October 18, 2024 and a resolution passed in the extraordinary general meeting of its Shareholders held on October 18, 2024 following which the name of the company was changed to ‘Anthem Biosciences Limited’ and a certificate of incorporation consequent upon conversion to public limited company was issued by the RoC on December 10, 2024.
The company is an innovation-driven and technology-focused Contract Research, Development and Manufacturing Organization (CRDMO) with fully integrated operations spanning across drug discovery, development and manufacturing with integrated New Chemical Entity (NCE) and New Biological Entity (NBE) capabilities across drug discovery, development, and commercial manufacturing. It provides end to end CRDMO services and it serves a range of customers, encompassing innovator-focused emerging biotech and large pharmaceutical companies globally.
Its CRDMO platform comprises main modalities (RNAi, ADC, peptides, lipids and oligonucleotides) and manufacturing capabilities (custom synthesis, flow chemistry, fermentation and biotransformation). It derives revenue primarily from its CRDMO services, including developmental and commercial manufacturing, and research and development services. It also generates revenue from the manufacture and sale of specialty ingredients.
Business area of the company
Anthem Biosciences has been set up as a Life sciences/ Biotechnology based venture specialising in the manufacture of catalytic preparation, other organic compounds such as speciality organic molecules, biologically active peptides etc., which are high-value products used in drug, agrochemical and speciality chemicals industries.
Awards, accreditations, and recognition
- 2023: Received a certificate of recognition as a ‘Four Star Export House’ from the Ministry of Commerce and Industry.
- 2023: Received an accreditation from AAALAC International.
- 2023: Received the Bureau Veritas Certification for achieving the ISO 9001:2015, ISO 14001:2015 & ISO 45001:2018 standards.
- 2024: Received the certification as a foreign drug manufacturer issued by the Minister of Health, Labour and Welfare.
- 2024: Received the ‘Pharma Excellence Award’ for excellence in contribution towards sustainability issued by ASSOCHAM.
- 2025: Received a certificate of appreciation in recognition of appreciable achievement in occupation safety and health during 2021-2023 from the National Safety Council of India Safety Awards - 2024.
- 2025: Received the State Level safety award under the category of Best Large Scale Industry.
History and milestones
- 2006: Incorporation of the company.
- 2007: Commenced operations of the company at Unit I and set up a custom synthesis plant with a capacity of 6 KL.
- 2008: Commencement of the discovery biology services with a fermentation capacity of 2 KL.
- 2010: Expanded the custom synthesis plant set up at Unit I increasing its capacity from 6 KL to 24 KL.
- 2013: Received the first USFDA audit approval for Unit I.
- 2016: Set up a high potent lab at Unit I - Bommasandra Facility.
- 2017: The company, pursuant to an order dated November 30, 2017, amalgamated with Anthem Cellutions (India) Private Limited by way of an acquisition of 100% of its share capital.
- 2017: Set up a solid phase peptide synthesis GMP lab with a capacity of 6 KL at Unit 1.
- 2017: Commenced operations of the Company at Unit II and set up an automated GMP compliant custom synthesis plant with a capacity of 128 KL and a fermentation plant with a capacity of 80 KL.
- 2017: Received the second USFDA audit approval for Unit I.
- 2018: Anthem Cellutions (India) Private Limited amalgamated into the company.
- 2019: Received the third USFDA approval for Unit I.
- 2019: Set up a flow chemistry lab at Unit I.
- 2020: Commenced operations in biological facility 2 earmarked for a specific client.
- 2022: Expanded the custom synthesis plant set up at Unit II increasing its capacity to 246 KL.
- 2023: Received the first USFDA audit approval and first therapeutic goods administration audit for Unit II.
- 2023: Addition of Oligonucleotide lab in Unit I.
- 2023: Set a cGMP scale continuous flow manufacturing facility for Unit II.
- 2024: Received the: second USFDA audit approval for Unit II; first ANVISA audit approval for Unit I; and first ANVISA audit approval for Unit II.
- 2024: Commenced operations of Neoanthem Lifesciences Private Limited, at Unit III designed as a chemistry lab and customer synthesis pilot plant for development, technology transfer and scale-up projects.
- 2024: Fermentation capacity expanded to 140 KL at Unit II.
- 2024: Conversion of the Company into a public limited company, under the name ‘Anthem Biosciences Limited’.
- 2025: Received the fourth USFDA approval for Unit I.
You have 49 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
